We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Curis has announced that a new report has documented the beneficial effects
of Hedgehog pathway stimulation for accelerated wound closure in an animal model
of diabetes-impaired wound healing.
Data presented at the National Kidney Foundation 2005 clinical meeting in Washington,
D.C., showed that, in vitro, Fosrenol binds phosphate across a broad pH range
with higher affinity than sevelamer HCl.
Sangamo BioSciences has initiated a Phase I clinical trial of SB-509, a novel
therapeutic designed to protect and stimulate the regeneration of peripheral
nerve function in diabetics suffering from peripheral neuropathy.
Keryx Biopharmaceuticals has reported interim data from the Phase II study titled,
"An exploratory, randomized, double-blind, multiple dose study of KRX-101
(sulodexide gelcaps) for the treatment of Type 2 diabetic nephropathy patients
with persistent microalbuminuria."
Astralis has reported the results of its 120-patient, 11-site, multidose Phase
II clinical trial of Psoraxine, its product for the treatment of psoriasis.
Peregrine Pharmaceuticals has submitted an investigational new drug application
(IND) to the FDA to initiate a Phase I clinical trial using Tarvacin to treat
patients with chronic hepatitis C virus infection.